Clinical trials show tirzepatide produces weight loss of 1522% when paired with lifestyle modification, yet access barriersincluding insurance denials and savings program exhaustionprevent millions from continuing treatment
L., Bernard, C., Lipshultz, S
6, Health and Human Services General Counsel Mike Stuart said the agency referred Hims & Hers to the Justice Department for "investigation for potential violations" of the Federal Food, Drug, and Cosmetic Act
While the medication itself is not detected by standard laboratory panels, understanding what blood work can and cannot reveal about tirzepatide is important for patients and healthcare providers
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, Brownstein MJ, Roth J (2023) Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Insurance Copay Ranges by Plan Type: The prior authorization process represents the most significant barrier to insurance-based GLP-1 treatment
